Stockreport

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market [Yahoo! Finance]

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization The FDA approval is based on ATTRibute-CM Phas [Read more]